
## **Chan-Bum Choi**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4641652/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. Journal of Rheumatology, 2007, 34, 706-11.	2.0	131
2	Common Variants within MECP2 Confer Risk of Systemic Lupus Erythematosus. PLoS ONE, 2008, 3, e1727.	2.5	125
3	Genomeâ€wide association study of rheumatoid arthritis in Koreans: Populationâ€specific loci as well as overlap with European susceptibility loci. Arthritis and Rheumatism, 2011, 63, 884-893.	6.7	121
4	Evaluation of imputation-based association in and around the integrin-Â-M (ITGAM) gene and replication of robust association between a non-synonymous functional variant within ITGAM and systemic lupus erythematosus (SLE). Human Molecular Genetics, 2009, 18, 1171-1180.	2.9	100
5	High-density genotyping of immune loci in Koreans and Europeans identifies eight new rheumatoid arthritis risk loci. Annals of the Rheumatic Diseases, 2015, 74, e13-e13.	0.9	100
6	Progress in defining clinically meaningful changes for clinical trials in nonrenal manifestations of SLE disease activity. Arthritis Research and Therapy, 2016, 18, 1.	3.5	80
7	Development of an algorithm for identifying rheumatoid arthritis in the Korean National Health Insurance claims database. Rheumatology International, 2013, 33, 2985-2992.	3.0	78
8	Prevalence and incidence of rheumatoid arthritis in South Korea. Rheumatology International, 2013, 33, 1525-1532.	3.0	62
9	Variation in the <i>ICAM1–ICAM4–ICAM5</i> locus is associated with systemic lupus erythematosus susceptibility in multiple ancestries. Annals of the Rheumatic Diseases, 2012, 71, 1809-1814.	0.9	60
10	Replication of the genetic effects of IFN regulatory factor 5 (IRF5) on systemic lupus erythematosus in a Korean population. Arthritis Research and Therapy, 2007, 9, R32.	3.5	56
11	ARTS1 polymorphisms are associated with ankylosing spondylitis in Koreans. Annals of the Rheumatic Diseases, 2010, 69, 582-584.	0.9	54
12	Korean Observational Study Network for Arthritis (KORONA): Establishment of a Prospective Multicenter Cohort for Rheumatoid Arthritis in South Korea. Seminars in Arthritis and Rheumatism, 2012, 41, 745-751.	3.4	54
13	Evaluation of <i>TRAF6</i> in a large multiancestral lupus cohort. Arthritis and Rheumatism, 2012, 64, 1960-1969.	6.7	51
14	Association of Anti–Cyclic citrullinated peptide antibody levels with PADI4 haplotypes in early rheumatoid arthritis and with shared epitope alleles in very late rheumatoid arthritis. Arthritis and Rheumatism, 2007, 56, 1454-1463.	6.7	48
15	Effect of n-3 polyunsaturated fatty acid supplementation in patients with rheumatoid arthritis: a 16-week randomized, double-blind, placebo-controlled, parallel-design multicenter study in Korea. Journal of Nutritional Biochemistry, 2013, 24, 1367-1372.	4.2	45
16	Do Patients with Elderly-Onset Rheumatoid Arthritis Have Severe Functional Disability?. Seminars in Arthritis and Rheumatism, 2012, 42, 23-31.	3.4	43
17	Impact of interstitial lung disease on mortality of patients with rheumatoid arthritis. Rheumatology International, 2017, 37, 1735-1745.	3.0	43
18	The Prevalence and Trend of Arthritis in Korea: Results from Korea National Health and Nutrition Examination Surveys. The Journal of the Korean Rheumatism Association, 2008, 15, 11.	0.1	42

#	Article	IF	CITATIONS
19	A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study. Annals of the Rheumatic Diseases, 2017, 76, 65-71.	0.9	39
20	The frequency of and risk factors for osteoporosis in Korean patients with rheumatoid arthritis. BMC Musculoskeletal Disorders, 2016, 17, 98.	1.9	38
21	The â^'169C/T polymorphism inFCRL3 is not associated with susceptibility to rheumatoid arthritis or systemic lupus erythematosus in a case–control study of Koreans. Arthritis and Rheumatism, 2006, 54, 3838-3841.	6.7	37
22	Clinical characteristics and outcomes of diffuse alveolar hemorrhage in patients with systemic lupus erythematosus. Seminars in Arthritis and Rheumatism, 2017, 46, 782-787.	3.4	36
23	Peptidyl arginine deiminase type IV (PADI4) haplotypes interact with shared epitope regardless of anti-cyclic citrullinated peptide antibody or erosive joint status in rheumatoid arthritis: a case control study. Arthritis Research and Therapy, 2010, 12, R115.	3.5	35
24	Incidence and risk factors of fractures in patients with rheumatoid arthritis: an Asian prospective cohort study. Rheumatology International, 2016, 36, 1205-1214.	3.0	35
25	Mortality and Incidence of Malignancy in Korean Patients with Rheumatoid Arthritis. Journal of Rheumatology, 2012, 39, 226-232.	2.0	32
26	Glucocorticoid Use in Patients With Systemic Lupus Erythematosus: Association Between Dose and Health Care Utilization and Costs. Arthritis Care and Research, 2015, 67, 1086-1094.	3.4	32
27	Factors Influencing Discrepancies Between the QuantiFERON-TB Gold in Tube Test and the Tuberculin Skin Test in Korean Patients with Rheumatic Diseases. Seminars in Arthritis and Rheumatism, 2013, 42, 424-432.	3.4	31
28	Impact of comorbidities on TNF inhibitor persistence in rheumatoid arthritis patients: an analysis of Korean National Health Insurance claims data. Rheumatology International, 2012, 32, 3851-3856.	3.0	28
29	Drug retention and safety of TNF inhibitors in elderly patients with rheumatoid arthritis. BMC Musculoskeletal Disorders, 2016, 17, 333.	1.9	28
30	Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in Korea: A Narrative Review. Yonsei Medical Journal, 2019, 60, 10.	2.2	27
31	Adverse events in analgesic treatment with tramadol associated with CYP2D6 extensive-metaboliser and OPRM1 high-expression variants. Annals of the Rheumatic Diseases, 2010, 69, 1889-1890.	0.9	26
32	Genome-wide association study in a Korean population identifies six novel susceptibility loci for rheumatoid arthritis. Annals of the Rheumatic Diseases, 2020, 79, 1438-1445.	0.9	26
33	Survival and prognostic factors in patients with connective tissue diseaseâ€associated pulmonary hypertension diagnosed by echocardiography: results from a Korean nationwide registry. International Journal of Rheumatic Diseases, 2017, 20, 1227-1236.	1.9	24
34	A 2-Week, multicenter, randomized, double-blind, double-dummy, add-on study of the effects of titration on tolerability of tramadol/acetaminophen combination tablet in Korean adults with knee osteoarthritis pain. Clinical Therapeutics, 2007, 29, 1381-1389.	2.5	23
35	Prevalence and possible causes of hypouricemia at a tertiary care hospital. Korean Journal of Internal Medicine, 2016, 31, 971-976.	1.7	23
36	Association-heterogeneity mapping identifies an Asian-specific association of the GTF2I locus with rheumatoid arthritis. Scientific Reports, 2016, 6, 27563.	3.3	23

#	Article	IF	CITATIONS
37	Imputing Variants in HLA-DR Beta Genes Reveals That HLA-DRB1 Is Solely Associated with Rheumatoid Arthritis and Systemic Lupus Erythematosus. PLoS ONE, 2016, 11, e0150283.	2.5	20
38	Analysis of single nucleotide polymorphisms in Toll-like receptor 4 shows no association with ankylosing spondylitis in a Korean population. Rheumatology International, 2008, 28, 627-630.	3.0	19
39	Factors Associated with the Use of Complementary and Alternative Medicine for Korean Patients with Rheumatoid Arthritis. Journal of Rheumatology, 2015, 42, 2075-2081.	2.0	19
40	KOBIO, the First Web-based Korean Biologics Registry Operated With a Unified Platform Among Distinct Disease Entities. Journal of Rheumatic Diseases, 2021, 28, 176-182.	1.1	19
41	Factors associated with time to diagnosis from symptom onset in patients with early rheumatoid arthritis. Korean Journal of Internal Medicine, 2019, 34, 910-916.	1.7	19
42	Mapping health assessment questionnaire disability index (HAQ-DI) score, pain visual analog scale (VAS), and disease activity score in 28 joints (DAS28) onto the EuroQol-5D (EQ-5D) utility score with the KORean Observational study Network for Arthritis (KORONA) registry data. Rheumatology International, 2016, 36, 505-513.	3.0	18
43	The major determinants of arterial stiffness in Korean patients with rheumatoid arthritis are age and systolic blood pressure, not disease-related factors. Rheumatology International, 2012, 32, 3455-3461.	3.0	17
44	Brief Report: Influence of HLA–DRB1 Susceptibility Alleles on the Clinical Subphenotypes of Systemic Lupus Erythematosus in Koreans. Arthritis and Rheumatology, 2016, 68, 1190-1196.	5.6	17
45	Different Genetic Effects of Interferon Regulatory Factor 5 (IRF5) Polymorphisms on Systemic Lupus Erythematosus in a Korean Population. Journal of Rheumatology, 2008, 35, 2148-2151.	2.0	16
46	Mortality factors in idiopathic inflammatory myopathy: focusing on malignancy and interstitial lung disease. Modern Rheumatology, 2013, 23, 503-508.	1.8	16
47	What factors affect discordance between physicians and patients in the global assessment of disease activity in rheumatoid arthritis?. Modern Rheumatology, 2017, 27, 35-41.	1.8	16
48	Safety and Clinical Responses in Ankylosing Spondylitis after Three Months of Etanercept Therapy. Journal of Korean Medical Science, 2008, 23, 852.	2.5	15
49	Impact of early diagnosis on functional disability in rheumatoid arthritis. Korean Journal of Internal Medicine, 2017, 32, 738-746.	1.7	15
50	Caspase-1 Level in Synovial Fluid Is High in Patients with Spondyloarthropathy but Not in Patients with Gout. Journal of Korean Medical Science, 2013, 28, 1289.	2.5	12
51	DC-Based Immunotherapy Combined with Low-Dose Methotrexate Effective in the Treatment of Advanced CIA in Mice. Journal of Immunology Research, 2015, 2015, 1-15.	2.2	12
52	Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study. Arthritis Research and Therapy, 2019, 21, 122.	3.5	12
53	Eosinophilic Granulomatosis with Polyangiitis: Experiences in Korean Patients. Yonsei Medical Journal, 2019, 60, 705.	2.2	11
54	Evaluation of disease activity indices in Korean patients with rheumatoid arthritis. Rheumatology International, 2012, 32, 545-549.	3.0	10

#	Article	IF	CITATIONS
55	A case of microscopic polyangiitis associated with aortic valve insufficiency. Rheumatology International, 2013, 33, 1055-1058.	3.0	10
56	The Reliability and Validity of a Korean Translation of the ASAS Health Index and Environmental Factors in Korean Patients with Axial Spondyloarthritis. Journal of Korean Medical Science, 2014, 29, 334.	2.5	10
57	Characteristics and outcomes of rheumatoid arthritis patients who started biosimilar infliximab. Rheumatology International, 2017, 37, 1007-1014.	3.0	10
58	SKI306X inhibition of glycosaminoglycan degradation in human cartilage involves down-regulation of cytokine-induced catabolic genes. Korean Journal of Internal Medicine, 2014, 29, 647.	1.7	10
59	Characteristics of Korean Patients with RA: A Single Center Cohort Study. The Journal of the Korean Rheumatism Association, 2009, 16, 204.	0.1	10
60	Mortality factors in idiopathic inflammatory myopathy: focusing on malignancy and interstitial lung disease. Modern Rheumatology, 2013, 23, 503-508.	1.8	10
61	Evaluation of the usefulness of interferonâ€gamma release assays and the tuberculin skin test for the detection of latent <i>Mycobacterium tuberculosis</i> infections in Korean rheumatic patients who are candidates for biologic agents. International Journal of Rheumatic Diseases, 2015, 18, 315-322.	1.9	9
62	Prevalence and Associated Factors for Non-adherence in Patients with Rheumatoid Arthritis. Journal of Rheumatic Diseases, 2018, 25, 47.	1.1	9
63	Comparative effectiveness of treatment options after conventional DMARDs failure in rheumatoid arthritis. Rheumatology International, 2017, 37, 975-982.	3.0	8
64	Postsplenectomy Recurrence of Thrombocytopenia with an Accessory Spleen. Korean Journal of Internal Medicine, 2004, 19, 199-201.	1.7	8
65	Risk factors for herpes zoster in Korean patients with rheumatoid arthritis treated with JAK inhibitor: a nested case–control study. RMD Open, 2022, 8, e001892.	3.8	8
66	Prevalence and factors affecting glucosamine use in Korea: a survey-based study. Rheumatology International, 2013, 33, 1627-1631.	3.0	7
67	A comparison of incidence and risk factors for serious adverse events in rheumatoid arthritis patients with etanercept or adalimumab in Korea and Japan. Modern Rheumatology, 2014, 24, 572-579.	1.8	7
68	Factors Contributing to Discordance between the 2011 ACR/EULAR Criteria and Physician Clinical Judgment for the Identification of Remission in Patients with Rheumatoid Arthritis. Journal of Korean Medical Science, 2016, 31, 1907.	2.5	7
69	Clinical and Genetic Risk Factors Associated With the Presence of Lupus Nephritis. Journal of Rheumatic Diseases, 2021, 28, 150-158.	1.1	7
70	Prediction for TNF Inhibitor Users in RA Patients According to Reimbursement Criteria Based on DAS28. Journal of Rheumatic Diseases, 2014, 21, 64.	1.1	6
71	An Internet-based technique for the identification of persons with symptoms of inflammatory polyarthritis of less than 12Âweeks. Clinical Rheumatology, 2015, 34, 465-470.	2.2	6
72	Effect of lower dose intravenous cyclophosphamide on remission induction in Korean patients with lupus nephritis. Rheumatology International, 2008, 28, 453-458.	3.0	5

#	Article	IF	CITATIONS
73	Clinical experience with tumor necrosis factor blockers in Korean rheumatoid arthritis patients. APLAR Journal of Rheumatology, 2006, 9, 146-149.	0.2	4
74	Impact of Change in Reimbursement Guideline of Rheumatoid Arthritis on the Short Term Persistence of Tumor Necrosis Factor (TNF) Blockers. Journal of Rheumatic Diseases, 2011, 18, 283.	1.1	4
75	Improving Participation in Clinical Trials of Novel Therapies. Rheumatic Disease Clinics of North America, 2014, 40, 553-559.	1.9	4
76	Treatment Persistence with TNF Blocker in Korean Rheumatoid Arthritis Patients. Journal of Rheumatic Diseases, 2011, 18, 161.	1.1	3
77	Incidence of Tuberculosis in Rheumatoid Arthritis Patients Using Anti-Tumor Necrosis Factor Agents following Latent Tuberculosis Infection Screening Strategies. Journal of Rheumatic Diseases, 2015, 22, 223.	1.1	3
78	Isoniazid treatment for latent tuberculosis infection is tolerable for rheumatoid arthritis patients receiving tumor necrosis factor inhibitor therapy. Korean Journal of Internal Medicine, 2018, 33, 1016-1024.	1.7	3
79	Safety and tolerability of bone marrow–derived mesenchymal stem cells in lupus animal models and a phase I clinical trial in humans. Lupus, 2022, 31, 1245-1253.	1.6	3
80	Gastrointestinal Risk Factors and Non-steroidal Anti-inflammatory Drugs Use in Rheumatoid Arthritis and Osteoarthritis Patients in Korea. Journal of Rheumatic Diseases, 2016, 23, 47.	1.1	2
81	Fracture Risk and its Prevention Patterns in Korean Patients with Polymyalgia Rheumatica: a Retrospective Cohort Study. Journal of Korean Medical Science, 2021, 36, e263.	2.5	2
82	Clinicial Significance of Spontaneous Pneumomediastinum in Dermatomyositis/Polymyositis. The Journal of the Korean Rheumatism Association, 2010, 17, 143.	0.1	1
83	Agreement of Major Diagnosis and Comorbidity between Self-reported Questionnaire and Medical Record Review in Patients with Rheumatic Disease. Journal of Rheumatic Diseases, 2016, 23, 348.	1.1	1
84	Long-term Outcomes of Autologous Peripheral Blood Stem Cell Transplantation for Refractory Rheumatic Diseases. Journal of Rheumatic Diseases, 2017, 24, 149.	1.1	1
85	Deletion at 2q14.3 is associated with worse response to TNF-α blockers in patients with rheumatoid arthritis. Arthritis Research and Therapy, 2019, 21, 195.	3.5	1
86	Fate of Abstracts Presented at the Korean College of Rheumatology Annual Scientific Meetings. Journal of Rheumatic Diseases, 2019, 26, 41.	1.1	1
87	Switching from TNFα inhibitor to tacrolimus as maintenance therapy in rheumatoid arthritis after achieving low disease activity with TNFα inhibitors and methotrexate: 24-week result from a non-randomized, prospective, active-controlled trial. Arthritis Research and Therapy, 2021, 23, 182.	3.5	1
88	Sa.9. Common Variants within MECP2 Confer Risk of Systemic Lupus Erythematosus. Clinical Immunology, 2008, 127, S83.	3.2	0
89	A Case of Intestinal Behçet's Disease Complicated Enterocutanous Fistula with a Good Response to Adalimumab. Journal of Rheumatic Diseases, 2012, 19, 147.	1.1	0
90	Congenital Hypoplasia of the Medial Hallucial Sesamoid with Avascular Necrosis: A Case Report. Journal of the Korean Society of Radiology, 2013, 69, 311.	0.2	0

#	Article	lF	CITATIONS
91	Clinical outcomes of patients with active rheumatoid arthritis with normal acute phase reactant values. International Journal of Rheumatic Diseases, 2019, 22, 852-859.	1.9	0
92	AB1273â€ESTABLISHMENT OF A PROSPECTIVE COHORT FOR RHEUMATOID ARTHRITIS PATIENTS WITH INTERSTITIAL LUNG DISEASE: COMPARISON OF BASELINE CHARACTERISTICS BETWEEN RHEUMATOID ARTHRITIS PATIENT WITH OR WITHOUT INTERSTITIAL LUNG DISEASE. , 2019, , .		0
93	259â€Healthcare system affecting systemic lupus erythematosus in asia-pacific countries. , 2019, , .		0
94	What Can Lipids in Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis Tell Us?. Journal of Rheumatic Diseases, 2021, 28, 1-3.	1.1	0